Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
Total Valuation
RAPT Therapeutics has a market cap or net worth of $1.01B. The enterprise value is $540.63M.
Market Cap$1.01B
Enterprise Value$540.63M
Share Statistics
RAPT Therapeutics has 27,710,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,710,870
Owned by Insiders7.36%
Owned by Institutions36.42%
Financial Efficiency
RAPT Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -69.15%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-69.15%
Return on Capital Employed (ROCE)-0.71
Revenue Per Employee0.00
Profits Per Employee-1.94M
Employee Count67
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of RAPT Therapeutics is ―. RAPT Therapeutics’s PEG ratio is -0.86.
PE Ratio―
PS Ratio0.00
PB Ratio2.71
Price to Fair Value2.71
Price to FCF-6.18
Price to Operating Cash Flow-9.10
PEG Ratio-0.86
Income Statement
In the last 12 months, RAPT Therapeutics had revenue of 0.00 and earned -129.87M in profits. Earnings per share was -25.49.
Revenue0.00
Gross Profit0.00
Operating Income-136.10M
Pretax Income-129.87M
Net Income-129.87M
EBITDA-134.90M
Earnings Per Share (EPS)-25.49
Cash Flow
In the last 12 months, operating cash flow was -86.58M and capital expenditures -84.00K, giving a free cash flow of -86.66M billion.
Operating Cash Flow-86.58M
Free Cash Flow-86.66M
Free Cash Flow per Share-3.13
Dividends & Yields
RAPT Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change405.49%
50-Day Moving Average30.33
200-Day Moving Average15.49
Relative Strength Index (RSI)68.40
Average Volume (3m)388.50K
Important Dates
RAPT Therapeutics upcoming earnings date is Mar 5, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
RAPT Therapeutics as a current ratio of 4.87, with Debt / Equity ratio of 1.71%
Current Ratio4.87
Quick Ratio4.87
Debt to Market Cap<0.01
Net Debt to EBITDA1.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, RAPT Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
RAPT Therapeutics EV to EBITDA ratio is -2.77, with an EV/FCF ratio of -4.20.
EV to Sales0.00
EV to EBITDA-2.77
EV to Free Cash Flow-4.20
EV to Operating Cash Flow-4.20
Balance Sheet
RAPT Therapeutics has $157.34M in cash and marketable securities with $2.60M in debt, giving a net cash position of $154.75M billion.
Cash & Marketable Securities$157.34M
Total Debt$2.60M
Net Cash$154.75M
Net Cash Per Share$5.58
Tangible Book Value Per Share$4.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for RAPT Therapeutics is $64.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$64.38
Price Target Upside74.95% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast50.23%